DdI susceptibility of HIV-1 isolates in patients on long-term therapy. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


DdI susceptibility of HIV-1 isolates in patients on long-term therapy.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:107 (poster no. 64). Unique Identifier : AIDSLINE ASHM5/94348924
Land S; McGavin C; Corby S; Tyssen D; Gorry P; Magliano D; Birch C; State HIV Isolation Laboratory, Virology Department, Fairfield; Hospital, Victoria.

Abstract: Sequential HIV isolates obtained from 18 individuals receiving dideoxyinosine (ddI) were tested for susceptibility to the drug. All patients had received AZI before commencing ddI therapy for up to 18 months. Susceptibility assays were performed in peripheral blood lymphocytes infected with these isolates and maintained in 0.2 to 50 microM of ddI. The dose of infectious virus was standardised for each assay. The mean 50% inhibitory concentration of 35 pre-therapy and 48 post-therapy isolates was 3.4 microM (range, 0.1 microM to 12.5 microM) and 7.6 microM (range 0.1 microM to > 25 microM), respectively. Isolates from two patients showed greater than 10-fold increase in resistance to ddI after long term therapy. However, sequential isolates from the remaining patients showed no significant change in ddI susceptibility after up to 18 months of therapy. The emergence of HIV resistant to AZT occurs in about 50% of patients after 9 months of therapy. This contrasts with the development of ddI resistance which appears rarely or not at all after 18 months of therapy.
Keywords: Cells, Cultured Didanosine/*THERAPEUTIC USE Dose-Response Relationship, Drug Human HIV Infections/*DRUG THERAPY/MICROBIOLOGY HIV-1/*DRUG EFFECTS Long-Term Care Lymphocytes/MICROBIOLOGY Microbial Sensitivity Tests ABSTRACTKWDcells,cultureddidanosine/KWDtherapeuticusedose-responserelationship,drughumanhivinfections/KWDdrugtherapy/microbiologyhiv-1/KWDdrugeffectslong-termcarelymphocytes/microbiologymicrobialsensitivitytestsabstract
941230
M94C4303

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .